Described herein are tissue grafts derived from the placenta. The grafts are composed of at least one layer of amnion tissue where the epithelium layer has been substantially removed in order to expose the basement layer to host cells. By removing the epithelium layer, cells from the host can more readily interact with the cell-adhesion bio-active factors located onto top and within of the basement membrane. Also described herein are methods for making and using the tissue grafts. The laminin structure of amnion tissue is nearly identical to that of native human tissue such as, for example, oral mucosa tissue. This includes high level of laminin-5, a cell adhesion bio-active factor show to bind gingival epithelia-cells, found throughout upper portions of the basement membrane.

A scleral prosthesis includes an elongated body configured to be implanted into scleral tissue of an eye. The body includes (i) opposing first and second free ends and (ii) multiple first portions that form the first end of the body and part of a remainder of the body between the ends. The first portions are separated along at least about half of a total length of the body by empty space such that the first portions meet at a point between the ends and are not connected to each other between that point and the first end. The ends are wider than the remainder. The scleral prosthesis also includes an insert configured to be placed between the first portions and to substantially fill the empty space. The body includes a convex upper surface extending lengthwise between the ends. The insert includes a convex upper surface extending lengthwise along the insert.

A scleral prosthesis includes an elongated body configured to be implanted into scleral tissue of an eye. The elongated body includes (i) opposing first and second free ends and (ii) multiple first portions that form the first end of the body and part of a remainder of the body between the first and second ends. The first and second ends are wider than the remainder of the body. The first portions are separated by empty space such that the first portions meet at a point between the first and second ends and are not connected to each other between that point and the first end. The first end projects beyond one or more sides of the remainder of the body and angles back towards the second end. The second end projects beyond the one or more sides of the remainder of the body and angles back towards the first end.

Segmented scaffolds composed of disconnected scaffold segments with overlapping end rings are disclosed. Scaffolds with at least one discontinuous link are also disclosed.

A scleral prosthesis includes an elongated body and an insert. The body includes (i) opposing first and second free ends and (ii) multiple first portions that form the first end and part of a remainder of the body between the ends. The first portions are separated along at least about half of a total length of the body by empty space such that the first portions meet at a point between the ends and are not connected to each other between that point and the first end. The ends are wider than the remainder. The insert is configured to be placed between the first portions and to substantially fill the empty space. The first portions are biased so that they maintain separation from one another without external interference but are configured to be pushed towards each other in order to reduce a width of the first end. The insert, when placed between the first portions, keeps the first portions separated and prevents the first portions from being pushed together and reducing the width of the first end.

A scleral prosthesis includes an elongated body configured to be implanted into scleral tissue of an eye. The body includes (i) opposing first and second free ends and (ii) a pair of first portions that form the first end and part of a remainder of the body between the ends. The first portions are separated along at least about half of a total length of the body by empty space such that the first portions meet at a point between the ends and are not connected to each other between that point and the first end. The ends are wider than the remainder. The scleral prosthesis also includes an insert configured to be placed between the first portions and to substantially fill the empty space. The insert, prior to insertion, includes one or more slots. The first portions include one or more ridges configured to engage with the one or more slots of the insert.

A holder for a hybrid heart valve prosthesis that can be quickly and easily implanted during a surgical procedure is provided. The hybrid heart valve includes a non-expandable, non-compressible prosthetic valve and a self-expandable anchoring stent, thereby enabling attachment to the annulus without sutures. A first suture connects the holder to the valve and constricts an inflow end of the anchoring stent. A second suture connects the holder to the valve and extends down three holder legs to loop through fabric on the valve. Both sutures may loop over a single cutting well on the holder so that severing the first and second sutures at the single cutting well simultaneously releases the tension in the first suture, permitting the inflow end of the anchoring stent to expand, and disconnects the valve holder from the prosthetic heart valve.

Heart valve delivery systems and methods for providing a clinician with feedback during a stented prosthetic heart valve delivery procedure. Feedback is provided using piezochromatic indicators incorporated into elements of the delivery device, such as the handle assembly, shaft assembly and capsule to indicate when detrimental forces, or forces nearing those that are detrimental, are being applied to the delivery device during the prosthetic heart valve loading, delivery or deployment procedure. Other embodiments incorporate a feedback indicator to indicate that a delivery device has previously been used and is not in a new condition.

Provided herein are various embodiments of an improved glenoid implant assembly that includes a baseplate, a polymer glenosphere, and an interfacing component. The interfacing component can be made of a material that is more rigid than the polymer glenosphere, has a bowl-shaped configuration with a convex side and a recessed side, where the convex side is configured to be secured to the circular recessed portion of the polymer glenosphere and the recessed side is configured to securely receive the baseplate. The interfacing component is interposed between the polymer glenosphere and the baseplate and provide a secure attachment between the polymer glenosphere and the baseplate.

A drug-eluting stent for insertion in a blood vessel includes a tubular mesh structure composed of a magnesium alloy and a poly-L-lactide layer that is micro arc oxidized disposed over the tubular mesh structure. The biodegradable drug-eluting stent further includes Zotarolimus and Rosuvastatin integrated into the poly-L-lactide layer to provide controlled and sustained drug release. Advantageously, wherein the drug-eluting stent is configured to be deployed in the blood vessel to provide drug delivery to a target site.